Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $7.5
Portfolio Pulse from richadhand@benzinga.com
Alliance Global Partners analyst James Molloy has initiated coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and a price target of $7.5.
July 17, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroSense Therapeutics has been given a Buy rating by Alliance Global Partners with a price target of $7.5.
The Buy rating and price target set by Alliance Global Partners indicate a positive outlook for NeuroSense Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100